Financial assets and liabilities - Summary of Valuation Processes of Contingent Consideration at Fair Value (Details) - USD ($) $ in Thousands |
Dec. 31, 2025 |
Jun. 30, 2025 |
|---|---|---|
| Disclosure Of Financial Assets And Liabilities [Abstract] | ||
| Fair value of cash or stock payable, dependent on achievement of future late-stage clinical or regulatory targets | $ 11,021 | $ 10,778 |
| Fair value of financial derivative liability | 2,218 | 10,262 |
| Fair value of royalty payments from commercialization of the intellectual property acquired | 899 | 739 |
| Contingent consideration | $ 14,138 | $ 21,779 |